{"id":"https://genegraph.clinicalgenome.org/r/bc64abd3-c64b-444a-ac7b-51768f9e07d9v1.0","type":"EvidenceStrengthAssertion","dc:description":"The *FOXE3* gene was first reported in relation to ocular disease in 2001, in affected members of a family who inherited anterior segment dysgenesis and cataracts in an autosomal dominant fashion (PMID: 11159941). The known spectrum of disease continued to expand with the 2006 identification of *FOXE3* variants in cases of congenital primary aphakia, with an autosomal recessive mode of inheritance (PMID: 16826526). *FOXE3* variants have since been identified as the basis for both autosomal recessive and autosomal dominant cases of congenital cataract (PMID: 17893665, PMID: 20806047), indicating the potential for a broad range of phenotypic presentations. Cases diagnosed with anterior segment dysgenesis 2 generally exhibit features such as congenital aphakia, aplasia or hypoplasia of the iris, microphthalmia, Peters anomaly, anterior chamber synechiae, corneal opacity, cataract, coloboma, reduced visual acuity, and/or developmental glaucoma. Cases diagnosed as cataract 34 generally present with congenital cataract either in isolation or accompanied by additional ocular features such as microphthalmia and/or corneal opacity. Cases with autosomal recessive inheritance generally have more severe presentation than those with autosomal dominant inheritance. Per criteria outlined by the ClinGen Lumping & Splitting Working Group, the phenotypic variability between cases of anterior segment dysgenesis 2 (MIM# 610256, MONDO:0014508) and cataract 34 (MIM# 612968) appears to represent a spectrum of disease rather than separate disease entities. Despite variability in the mode of inheritance across published cases, the molecular mechanism appears to be *FOXE3* loss of function, either by two null or hypomorphic alleles or one dominant negative allele. Therefore, cases caused by inherited *FOXE3* variants have been lumped into a single disease entity, referred to as FOXE3-related anterior segment dysgenesis, with a semidominant mode of inheritance.\n\nEleven suspected disease-causing variants were scored as part of this curation (one nonsense, two frameshift, four missense, and four stop-loss), which have been collectively reported in eleven probands in nine publications (PMID: 11159941, PMID: 16826526, PMID: 17893665, PMID: 19708017, PMID: 20140963, PMID: 20806047, PMID: 21150893, PMID: 25504734, PMID: 27218149). Four of the probands scored in this curation harbored a heterozygous stop-loss variant near the 3â€™ end of the *FOXE3* coding region, while the other seven probands harbored biallelic nonsense, frameshift, or missense *FOXE3* variants. Missense variants were generally located within the forkhead domain responsible for DNA binding. The mechanism of pathogenicity appears to be loss of *FOXE3* function conferred by either monoallelic dominant negative variants or biallelic null and/or hypomorphic variants. Null or hypmorphic variants do not appear to cause disease in the heterozygous state, as the carriers from families with autosomal recessive inheritance are all reportedly unaffected. Two families with segregation evidence contributed to the scoring of the gene-disease relationship (PMID: 17893665). Additional probands and family segregation evidence were available but not necessary to include, as the maximum scoring for these evidence types had already been reached.\n\nThis gene-disease association is also supported by biochemical evidence that *FOXE3* encodes a transcription factor that coordinates lens development through control of gene expression (PMID: 27218149). Consistent with this finding, *in situ* hybridization studies in mouse embryos have shown that *Foxe3* is specifically expressed in the developing lens (PMID: 10652278). Spontaneous and targeted mouse models of homozygous *Foxe3* disruption recapitulate human patient features such as microphakia, microcoria, microphthalmia, cataract, corneal opacity, corneolenticular adhesions (PMID: 10652278, PMID: 16199865). These models also provide additional insight into disease processes at the histological level, including reduced proliferation and enhanced apoptosis of lens epithelial cells (PMID: 10652278) and disrupted expression of key markers of eye development (PMID: 16199865).\n\nIn summary, *FOXE3* reached a definitive association with FOXE3-related anterior segment dysgenesis. This has been repeatedly demonstrated in both research and diagnostic settings, and has been upheld over time without the emergence of contradictory evidence, leading to a Definitive classification. This classification was approved by the ClinGen Glaucoma / Neuro-Opthalmology Gene Curation Expert Panel on July 20th, 2023 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/bc64abd3-c64b-444a-ac7b-51768f9e07d9","GCISnapshot":"https://genegraph.clinicalgenome.org/r/c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3","calculatedEvidenceStrength":"Moderate","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2025-04-15T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10077","date":"2025-05-16T15:19:56.853Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8f56e22b-0150-4324-8afd-2afe92806893","type":"EvidenceLine","dc:description":"The variant has been up-scored since it matches the pattern of dominant variants in FOXE3, but limited due to the lack of evidence of a dominant negative effect.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8f56e22b-0150-4324-8afd-2afe92806893_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Luciferase reporter experiments were performed to look for a dominant negative loss-of-function effect, however, no evidence was found of an effect on wild-type FOXE3 (PMID: 19708017, Figure 1).","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/8f56e22b-0150-4324-8afd-2afe92806893_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19708017","allele":{"id":"https://genegraph.clinicalgenome.org/r/8f22b7f9-8bb8-41d4-bb13-c155727fc163","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.958T>C (p.Ter320Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340251208"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/c646a143-e021-4076-b289-a88dc3df8fb4","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c646a143-e021-4076-b289-a88dc3df8fb4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_012186.3(FOXE3):c.720C>A (p.Cys240Ter) is a nonsense variant in exon 1 of 1 and is predicted to truncate the C-terminal 25% of the protein product.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c646a143-e021-4076-b289-a88dc3df8fb4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16826526","allele":{"id":"https://genegraph.clinicalgenome.org/r/7d994ac9-cb2d-43ce-9b0e-11267b724a35","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.720C>A (p.Cys240Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA119630"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/2a8c3c49-43d0-48f8-afc4-78dc43a321e1","type":"EvidenceLine","dc:description":"Scoring is recommended at 0.5 points (1 point total) since the variant is not subject to nonsense-mediated decay, and in order to moderately down-score for family consanguinity.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2a8c3c49-43d0-48f8-afc4-78dc43a321e1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of the variant into HEK-293 cells harboring the DNAJB1-GLuc-SEAP reporter vector was associated with decreased expression of luciferase, indicating loss of ability to transactivate expression of the target *DNAJB1*. Expression of the variant in HeLa or human lens epithelial cells reveals expression levels and nuclear localization comparable to wild-type.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2a8c3c49-43d0-48f8-afc4-78dc43a321e1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27218149","allele":{"id":"https://genegraph.clinicalgenome.org/r/7d994ac9-cb2d-43ce-9b0e-11267b724a35"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/28a61d99-14df-46dc-a473-7f39182f9a58","type":"EvidenceLine","dc:description":"The variant has been up-scored for functional evidence of a deleterious effect on FOXE3 function, but down-scored for family consanguinity and the limitations of the genotyping method.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/28a61d99-14df-46dc-a473-7f39182f9a58_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_012186.3(FOXE3):c.358C>G (p.Arg120Gly) is a missense variant in the DNA binding domain that has been shown to trigger complete loss of DNA binding (PMID: 25504734, Figure 1F). Ability to activate gene expression from a FOXE3 target promoter in a luciferase reporter assay was also significantly reduced (Figure 1H).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/28a61d99-14df-46dc-a473-7f39182f9a58_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25504734","allele":{"id":"https://genegraph.clinicalgenome.org/r/6365ee65-c42b-41df-b730-fa423070a2af","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.358C>G (p.Arg120Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340249701"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/80cad60e-3d09-4582-8776-f2adb1568926","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/80cad60e-3d09-4582-8776-f2adb1568926_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The exogenously expressed variant showed similar DNA binding capacity to the wild-type in an electrophoretic mobility shift assay (Figure 5B) but approximately 30% of wild-type expression at the protein level (Figure 4C).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/80cad60e-3d09-4582-8776-f2adb1568926_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20140963","allele":{"id":"https://genegraph.clinicalgenome.org/r/c563894d-a754-4a1e-8e42-fd9df02c40c9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.705del (p.Glu236SerfsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA522813511"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c6ab6af-556a-4942-beac-7a16ccb9ab3b_proband_segregation","type":"FamilyCosegregation","dc:description":"Whole exome sequencing has been used to rule out the presence of alternative causes of disease in two affected family members. The pedigree meets the requirements for inclusion in the final aggregate calculation.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17893665","rdfs:label":"Butt_2007_Family_PKCC039","family":{"id":"https://genegraph.clinicalgenome.org/r/1c6ab6af-556a-4942-beac-7a16ccb9ab3b","type":"Family","rdfs:label":"Butt_2007_Family_PKCC039"},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":7,"phenotypes":"obo:HP_0007787","proband":{"id":"https://genegraph.clinicalgenome.org/r/fa3c776b-acb5-4cfd-ac3b-bce94981985c"},"publishedLodScore":4.83,"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/765f086c-832d-4aef-9e08-3c4e8869cde7_proband_segregation","type":"FamilyCosegregation","dc:description":"The pedigree meets the criteria for inclusion in final calculation. Whole exome sequencing has ruled out alternative causes of disease in two affected family members.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17893665","rdfs:label":"Butt_2007_Family_PKCC009","family":{"id":"https://genegraph.clinicalgenome.org/r/765f086c-832d-4aef-9e08-3c4e8869cde7","type":"Family","rdfs:label":"Butt_2007_Family_PKCC009"},"meetsInclusionCriteria":true,"phenotypeFreeText":"Individual affected family members exhibit phenotypes such as corneal opacities, microcornea, and nystagmus.","phenotypeNegativeAlleleNegative":4,"phenotypePositiveAllelePositive":5,"phenotypes":"obo:HP_0010922","proband":{"id":"https://genegraph.clinicalgenome.org/r/b24624cc-cc59-478f-910e-dffbd017ac51"},"publishedLodScore":4.14,"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/9e9c2fd1-372e-4a64-993d-f1fb450d31e1","type":"EvidenceLine","dc:description":"NM_012186.3(FOXE3):c.21_24del (p.Met7fs) is a frameshift variant in exon 1 of 1 and is predicted to truncate ~98% of the C-terminus and replace it with 216 abnormal amino acids. Down-scoring has been performed for consanguinity and lack of prediction of nonsense-mediated decay.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e9c2fd1-372e-4a64-993d-f1fb450d31e1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19708017","allele":{"id":"https://genegraph.clinicalgenome.org/r/f8b04370-655b-4340-bde3-6e63ac0be27e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.21_24del (p.Met7IlefsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA522813454"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/ef205fc8-ed86-4945-a365-fa9c42149884","type":"EvidenceLine","dc:description":"The variant has been up-scored for compatibility with the established pattern that dominant variants in FOXE3 disrupt the stop codon and add abnormal sequence at the C-terminus of the protein product, but the evidence of mRNA instability was not considered.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef205fc8-ed86-4945-a365-fa9c42149884_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RNA isolated from lymphoblasts was found to contain wild-type but not variant mRNA, indicating that there variant may be degraded at the RNA level. Results were not considered due to incompatibility with the mode of inheritance and previous findings that FOXE3 is a lens-specific gene.","functionalDataSupport":"No"},{"id":"https://genegraph.clinicalgenome.org/r/ef205fc8-ed86-4945-a365-fa9c42149884_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21150893","allele":{"id":"https://genegraph.clinicalgenome.org/r/1ff94001-e511-4ab9-927d-fc832c2a532a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.959G>T (p.Ter320Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA128991"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/d7f5ee3c-5edf-4b4d-bb31-4a37dd5bfa33","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7f5ee3c-5edf-4b4d-bb31-4a37dd5bfa33_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"The variant has reduced expression (26% of wild-type) at the protein level (PMID: 34046667).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d7f5ee3c-5edf-4b4d-bb31-4a37dd5bfa33_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11159941","allele":{"id":"https://genegraph.clinicalgenome.org/r/4686ef71-b31b-49bb-a6de-b6556ae64494","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.942dup (p.Leu315AlafsTer?)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913184935"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/d1582538-413e-4f40-93f6-72b535c20834","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d1582538-413e-4f40-93f6-72b535c20834_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Exogenously expressed p.Met82Val showed reduced DNA-binding capacity in an electrophoretic mobility shift assay (<50% of wild-type, Figure 5B).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/d1582538-413e-4f40-93f6-72b535c20834_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20140963","allele":{"id":"https://genegraph.clinicalgenome.org/r/5aafd601-553c-458e-a9fe-24d3f76aa906","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.244A>G (p.Met82Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA842920"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria"},{"id":"https://genegraph.clinicalgenome.org/r/182af6e8-541c-4290-96f2-36776cfccc4f","type":"EvidenceLine","dc:description":"The variant has been up-scored for matching the stop-loss pattern of all other known dominant FOXE3 variants, but functional evidence has not been used for further up-scoring.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/182af6e8-541c-4290-96f2-36776cfccc4f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"NM_012186.3(FOXE3):c.959G>C (p.Ter320Ser) is a stop-loss variant predicted to add 72 abnormal amino acids to the protein product. A separately reported functional study has shown that the variant has reduced expression/stability at the protein level (32% of wild-type) but retains the ability to bind DNA (PMID: 34046667).","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/182af6e8-541c-4290-96f2-36776cfccc4f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20806047","allele":{"id":"https://genegraph.clinicalgenome.org/r/0d147b94-da89-47af-b67f-7f44172e1b9e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_012186.3(FOXE3):c.959G>C (p.Ter320Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA340251212"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/502cf3f4-f6cb-4850-99c5-377828197f74","type":"EvidenceLine","dc:description":"Although this curation has already scored another homozygous mouse model that similarly recapitulates human disease phenotypes, this model has the additional feature of targeted disruption of the Foxe3 locus. The disruption of markers of anterior segment development further helps explain the timing of Foxe3 importance in the formation of this tissue. Default scoring is considered appropriate for this reason.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/541ea016-1a5d-46e6-9187-d808b6ac6871","type":"Finding","dc:description":"The model exhibits eye abnormalities such as much smaller eyes (Fig. 2C) in which the pupil is particularly small (Fig. 2D) and the anterior chamber is absent (Figs. 2J, 2L). Additional abnormalities include retinal folding (Figs. 2F-2H), multilayered anterior lens epithelium (Figs. 2K, 2L), thin corneal epithelium (Fig. 2L), and corneolenticular adhesion (Fig. 3E). Some affected animals had eyes that never opened. Expression of other key markers of eye development, such as Prox1, is disrupted (Figs. 5C, 5D).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/16199865","rdfs:label":"Targeted knockout mouse model of Foxe3","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3c254116-dde2-45da-a971-c825bb137c77","type":"EvidenceLine","dc:description":"Default scoring is considered appropriate as the model recapitulates the mode of inheritance as well as the key ocular features of the human patients including anterior segment dysgenesis and cataract development.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/77a05c61-9c50-4793-83e0-4dbc2b7ddd0e","type":"Finding","dc:description":"The model exhibits eye abnormalities such as reduced proliferation of the lens epithelium (Fig. 3h, Fig. 5), small lens (Fig. 3d, Table 1), anterior lens cell apoptosis (Fig. 6o, 6p), absence of secondary lens fibers (Figs. 3g, 3h), cataract formation (Table 1), failure of the lens vesicle to separate from the cornea (Figs. 3d, 3f), ejection of lens material to the exterior (Fig. 3b), smaller eye (PMID: 109409), and corneal opacity (PMID: 109409).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10652278","rdfs:label":"The dyl mouse has spontaneous Foxe3 disruption","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aa2f9762-baa1-4ffa-9f59-2ccd58acf8d2","type":"EvidenceLine","dc:description":"Default scoring is considered appropriate since the biochemical function of FOXE3 is consistent with its proposed role in lens development and the early onset of lens defects in the human patients.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1b5173e4-bb86-4c04-bad6-1e15370a902f","type":"Finding","dc:description":"The article provides an example of the function of FOXE3 as a transcription factor, including a target gene with a key function in the lens.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27218149","rdfs:label":"FOXE3 encodes a transcription factor for lens development.","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6fc302fe-7cbb-45e8-ac64-d5e48585e0af","type":"EvidenceLine","dc:description":"Although FOXE3 expression across adult human tissues does not necessarily match the tissues affected in the disease state, embryonic staining in the mouse appears to be highly specific to the developing lens, identifying a role for the transcription factor in the proper development of this tissue. Default scoring is considered appropriate.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/91468ebf-363b-44f0-8a08-798c45d4acde","type":"Finding","dc:description":"Whole mount in situ hybridization between days E8.5 and E11.5 (and adult mice) found that FoxE3 is specifically expressed in the developing lens (Fig. 2), with the first rapid increase occurring during formation of the lens placode (Figs. 2b, 2g), later becoming confined to the lens vesicle (Fig. 2f), then switched off as these cells differentiate into lens fibers, but remaining expressed in undifferentiated cells on the lens anterior surface (Figs. 2h, 2i). Expression is also briefly seen in another area (the neural folds of the cephalic region, Fig. 2a). Please note that transcriptomic profiling of adult human tissues does not detect high expression in any of the ocular tissues tested, but rather finds FOXE3 expression peaking in the testis (PMID: 30239781).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10652278","rdfs:label":"Foxe3 is specifically expressed in developing mouse lens.","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5}],"evidenceStrength":"Moderate","sequence":10355,"specifiedBy":"GeneValidityCriteria9","strengthScore":8,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Q6LudXS9tLA","type":"GeneValidityProposition","disease":"obo:MONDO_0019503","gene":"hgnc:3808","modeOfInheritance":"obo:HP_0000005"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_c3d96af7-fd6a-4c40-b9db-3c1cd1df17a3-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}